Bernstein Harold, President of R&D and Chief Medical Officer, has demonstrated a clear selling bias in recent transactions involving MAZE, with no recorded purchases since at least September 2025. Over 24 reported transactions, his total sell activity amounts to $5.97 million, dwarfing his $1.41 million in buy activity. The bulk of his disposals occurred in concentrated bursts, including a $1.5 million sale on March 10, 2026, preceded by a $1.8 million combined sale on December 29, 2025. Notably, multiple transactions on single dates—such as three separate sales totaling $736,439 on March 20, 2026—suggest systematic divestment rather than isolated trades.
Harold’s sales frequently coincide with market acquisitions (coded "M"), where exercised options were immediately sold. For example, on March 10, 2026, he sold $1.49 million in shares alongside a $312,600 market acquisition, repeating a pattern seen in February and January 2026. The absence of open-market purchases and the recurring liquidation of equity awards indicate a strategy focused on monetizing vested holdings. While two March 2026 awards (coded "A") carried no reported value, their timing aligns with his broader disposition trend. All activity remains confined to MAZE, with no diversification into other securities. The consistency and scale of sales—particularly the multi-million-dollar transactions in late 2025 and early 2026—highlight a sustained reduction in exposure.
AI-assisted summary